|
|
Poland Pharmaceuticals and Healthcare Report Q1 2010Published by: Business Monitor International Published: Nov. 10, 2009 - 82 Pages Table of Contents
AbstractPoland is one of the highest value markets in Central and Eastern Europe (CEE) and as a result is adestination for almost all multinationals operating within the region. Poland’s pharmaceutical market hasshown consistently strong growth during 2009, despite economic pressures. Over the next 10 years BMIforecasts that pharmaceutical sales will record a compound annual growth rate (CAGR) of 7.9% in USdollar terms, highlighting its potential for foreign investors.Poland, however, does have a number of drawbacks which make it less than perfect, particularly for BigPharma. In BMI’s Q110 Business Environment Ratings, Poland places sixth out of the 20 CEE marketsin our coverage universe. While scoring relatively well in both pharmaceutical market and country riskcategories, demographic and market risk factors constrain a table-topping score. One of the majorfrustrations for multinationals is delays in reimbursement for innovative products and a strong preferencefor the domestic industry. Budgeted spending on healthcare by the National Health Fund (NFZ) has increased rapidly fromPLN33.1bn (US$10.2bn) in 2005 to PLN56.2bn (US$16.7bn) in 2009, a CAGR of 14.1%. Whileincreases for 2009 alone were lower at just 4.4%, the figures can still be viewed as positive for thehealthcare industry. Increases were seen across the majority of sub-sectors, including reimbursement ofpharmaceuticals. NFZ President Jacek Paszkiewicz believes that the fund’s budget for 2010 will have to be reduced byPLN2bn (US$686mn), which represents a 3.6% contraction on current 2009 budget figures. Furthermore,fund income in 2011 is set to drop further with reserves again required to support spending. Paszkiewiczexpects strikes within the healthcare sector as a result of a future inability to support wage demands. Regulatory updates mean a large number of food supplements, including vitamins and minerals, slimmingpreparations and dermatological products are likely to be withdrawn from sale in Poland from January 12010. Products which are currently available for sale without being registered as medicines will be forcedto obtain licences. Company-wise, biotechnology firm Bioton build strong international operations focused on insulin sales,biotechnological product development and strategic alliances. In late 2009 it was rumoured the firmwould extend it’s collaboration with Bayer-Schering to distribute recombinant insulin product SciLin inRussia, following a similar deal in China earlier in the year. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||